Gating on Annexin V/DAPI double negative events for viable cells, the percentage live cells remaining in the well after treatment of BCR-ABL1negative (normal) CD34+ cells with 1 μM each of nilotinib and IB, was approximately half the untreated control (e.g. 84 v 38%; Figure 5A) which was a greater surviving fraction than seen with treated CML-CP cells (1%, c.f. Figure 3A; p = 0.001 CML versus normal). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.